Literature DB >> 23878211

HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.

Tomer Hertz1, Christine M Oshansky, Philippa L Roddam, John P DeVincenzo, Miguela A Caniza, Nebojsa Jojic, Simon Mallal, Elizabeth Phillips, Ian James, M Elizabeth Halloran, Paul G Thomas, Lawrence Corey.   

Abstract

Experimental and computational evidence suggests that HLAs preferentially bind conserved regions of viral proteins, a concept we term "targeting efficiency," and that this preference may provide improved clearance of infection in several viral systems. To test this hypothesis, T-cell responses to A/H1N1 (2009) were measured from peripheral blood mononuclear cells obtained from a household cohort study performed during the 2009-2010 influenza season. We found that HLA targeting efficiency scores significantly correlated with IFN-γ enzyme-linked immunosorbent spot responses (P = 0.042, multiple regression). A further population-based analysis found that the carriage frequencies of the alleles with the lowest targeting efficiencies, A*24, were associated with pH1N1 mortality (r = 0.37, P = 0.031) and are common in certain indigenous populations in which increased pH1N1 morbidity has been reported. HLA efficiency scores and HLA use are associated with CD8 T-cell magnitude in humans after influenza infection. The computational tools used in this study may be useful predictors of potential morbidity and identify immunologic differences of new variant influenza strains more accurately than evolutionary sequence comparisons. Population-based studies of the relative frequency of these alleles in severe vs. mild influenza cases might advance clinical practices for severe H1N1 infections among genetically susceptible populations.

Entities:  

Keywords:  HLA association; MHC; Native American; T-cell epitope

Mesh:

Substances:

Year:  2013        PMID: 23878211      PMCID: PMC3746844          DOI: 10.1073/pnas.1221555110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.

Authors:  Angela Wahl; William McCoy; Fredda Schafer; Wilfried Bardet; Rico Buchli; Daved H Fremont; William H Hildebrand
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 2.  Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability.

Authors:  Paul Thiamjoo Tan; Asif M Khan; J Thomas August
Journal:  Hum Vaccin       Date:  2011-04-01

3.  Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study.

Authors:  Fatimah S Dawood; A Danielle Iuliano; Carrie Reed; Martin I Meltzer; David K Shay; Po-Yung Cheng; Don Bandaranayake; Robert F Breiman; W Abdullah Brooks; Philippe Buchy; Daniel R Feikin; Karen B Fowler; Aubree Gordon; Nguyen Tran Hien; Peter Horby; Q Sue Huang; Mark A Katz; Anand Krishnan; Renu Lal; Joel M Montgomery; Kåre Mølbak; Richard Pebody; Anne M Presanis; Hugo Razuri; Anneke Steens; Yeny O Tinoco; Jacco Wallinga; Hongjie Yu; Sirenda Vong; Joseph Bresee; Marc-Alain Widdowson
Journal:  Lancet Infect Dis       Date:  2012-06-26       Impact factor: 25.071

4.  Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus.

Authors:  Wei Zhang; Jianxun Qi; Yi Shi; Qing Li; Feng Gao; Yeping Sun; Xishan Lu; Qiong Lu; Christopher J Vavricka; Di Liu; Jinghua Yan; George F Gao
Journal:  Protein Cell       Date:  2010-06-04       Impact factor: 14.870

5.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

6.  2009 pandemic influenza A (H1N1) virus infections - Chicago, Illinois, April-July 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-08-28       Impact factor: 17.586

7.  2009 H1N1 fatalities: the New Mexico experience.

Authors:  Erin G Brooks; Clare H Bryce; Catherine Avery; Chad Smelser; Deborah Thompson; Kurt B Nolte
Journal:  J Forensic Sci       Date:  2012-05-09       Impact factor: 1.832

8.  T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.

Authors:  Teresa Lambe; Alexandra J Spencer; Caitlin E Mullarkey; Richard D Antrobus; Ly-Mee Yu; Philip de Whalley; Ben A V Thompson; Claire Jones; Jem Chalk; Simon Kerridge; Adrian V S Hill; Matthew D Snape; Andrew J Pollard; Sarah C Gilbert
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

9.  The impact of influenza A(H1N1)pdm09 compared with seasonal influenza on intensive care admissions in New South Wales, Australia, 2007 to 2010: a time series analysis.

Authors:  Andrea Schaffer; David Muscatello; Michelle Cretikos; Robin Gilmour; Sean Tobin; James Ward
Journal:  BMC Public Health       Date:  2012-10-12       Impact factor: 3.295

10.  Seroepidemiologic effects of influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore.

Authors:  James M Trauer; Don Bandaranayake; Robert Booy; Mark I Chen; Michelle Cretikos; Gary K Dowse; Dominic E Dwyer; Michael E Greenberg; Q Sue Huang; Gulam Khandaker; Jen Kok; Karen L Laurie; Vernon J Lee; Jodie McVernon; Scott Walter; Peter G Markey
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

View more
  25 in total

1.  Differences in the Epidemiology of Human Cases of Avian Influenza A(H7N9) and A(H5N1) Viruses Infection.

Authors:  Ying Qin; Peter W Horby; Tim K Tsang; Enfu Chen; Lidong Gao; Jianming Ou; Tran Hien Nguyen; Tran Nhu Duong; Viktor Gasimov; Luzhao Feng; Peng Wu; Hui Jiang; Xiang Ren; Zhibin Peng; Sa Li; Ming Li; Jiandong Zheng; Shelan Liu; Shixiong Hu; Rongtao Hong; Jeremy J Farrar; Gabriel M Leung; George F Gao; Benjamin J Cowling; Hongjie Yu
Journal:  Clin Infect Dis       Date:  2015-05-04       Impact factor: 9.079

2.  Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities.

Authors:  Sergio Quiñones-Parra; Emma Grant; Liyen Loh; Thi H O Nguyen; Kristy-Anne Campbell; Steven Y C Tong; Adrian Miller; Peter C Doherty; Dhanasekaran Vijaykrishna; Jamie Rossjohn; Stephanie Gras; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

3.  Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia.

Authors:  Pieter Meysman; Benson Ogunjimi; Stefan Naulaerts; Philippe Beutels; Viggo Van Tendeloo; Kris Laukens
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

Review 4.  Defining the risk of SARS-CoV-2 variants on immune protection.

Authors:  Marciela M DeGrace; Elodie Ghedin; Matthew B Frieman; Florian Krammer; Alba Grifoni; Arghavan Alisoltani; Galit Alter; Rama R Amara; Ralph S Baric; Dan H Barouch; Jesse D Bloom; Louis-Marie Bloyet; Gaston Bonenfant; Adrianus C M Boon; Eli A Boritz; Debbie L Bratt; Traci L Bricker; Liliana Brown; William J Buchser; Juan Manuel Carreño; Liel Cohen-Lavi; Tamarand L Darling; Meredith E Davis-Gardner; Bethany L Dearlove; Han Di; Meike Dittmann; Nicole A Doria-Rose; Daniel C Douek; Christian Drosten; Venkata-Viswanadh Edara; Ali Ellebedy; Thomas P Fabrizio; Guido Ferrari; Will M Fischer; William C Florence; Ron A M Fouchier; John Franks; Adolfo García-Sastre; Adam Godzik; Ana Silvia Gonzalez-Reiche; Aubree Gordon; Bart L Haagmans; Peter J Halfmann; David D Ho; Michael R Holbrook; Yaoxing Huang; Sarah L James; Lukasz Jaroszewski; Trushar Jeevan; Robert M Johnson; Terry C Jones; Astha Joshi; Yoshihiro Kawaoka; Lisa Kercher; Marion P G Koopmans; Bette Korber; Eilay Koren; Richard A Koup; Eric B LeGresley; Jacob E Lemieux; Mariel J Liebeskind; Zhuoming Liu; Brandi Livingston; James P Logue; Yang Luo; Adrian B McDermott; Margaret J McElrath; Victoria A Meliopoulos; Vineet D Menachery; David C Montefiori; Barbara Mühlemann; Vincent J Munster; Jenny E Munt; Manoj S Nair; Antonia Netzl; Anna M Niewiadomska; Sijy O'Dell; Andrew Pekosz; Stanley Perlman; Marjorie C Pontelli; Barry Rockx; Morgane Rolland; Paul W Rothlauf; Sinai Sacharen; Richard H Scheuermann; Stephen D Schmidt; Michael Schotsaert; Stacey Schultz-Cherry; Robert A Seder; Mayya Sedova; Alessandro Sette; Reed S Shabman; Xiaoying Shen; Pei-Yong Shi; Maulik Shukla; Viviana Simon; Spencer Stumpf; Nancy J Sullivan; Larissa B Thackray; James Theiler; Paul G Thomas; Sanja Trifkovic; Sina Türeli; Samuel A Turner; Maria A Vakaki; Harm van Bakel; Laura A VanBlargan; Leah R Vincent; Zachary S Wallace; Li Wang; Maple Wang; Pengfei Wang; Wei Wang; Scott C Weaver; Richard J Webby; Carol D Weiss; David E Wentworth; Stuart M Weston; Sean P J Whelan; Bradley M Whitener; Samuel H Wilks; Xuping Xie; Baoling Ying; Hyejin Yoon; Bin Zhou; Tomer Hertz; Derek J Smith; Michael S Diamond; Diane J Post; Mehul S Suthar
Journal:  Nature       Date:  2022-03-31       Impact factor: 69.504

5.  Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients.

Authors:  Thi H O Nguyen; Marios Koutsakos; Carolien E van de Sandt; Jeremy Chase Crawford; Liyen Loh; Sneha Sant; Ludivine Grzelak; Emma K Allen; Tim Brahm; E Bridie Clemens; Maria Auladell; Luca Hensen; Zhongfang Wang; Simone Nüssing; Xiaoxiao Jia; Patrick Günther; Adam K Wheatley; Stephen J Kent; Malet Aban; Yi-Mo Deng; Karen L Laurie; Aeron C Hurt; Stephanie Gras; Jamie Rossjohn; Jane Crowe; Jianqing Xu; David Jackson; Lorena E Brown; Nicole La Gruta; Weisan Chen; Peter C Doherty; Stephen J Turner; Tom C Kotsimbos; Paul G Thomas; Allen C Cheng; Katherine Kedzierska
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

6.  CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph.

Authors:  Luca Hensen; Patricia T Illing; E Bridie Clemens; Thi H O Nguyen; Marios Koutsakos; Carolien E van de Sandt; Nicole A Mifsud; Andrea T Nguyen; Christopher Szeto; Brendon Y Chua; Hanim Halim; Simone Rizzetto; Fabio Luciani; Liyen Loh; Emma J Grant; Phillipa M Saunders; Andrew G Brooks; Steve Rockman; Tom C Kotsimbos; Allen C Cheng; Michael Richards; Glen P Westall; Linda M Wakim; Thomas Loudovaris; Stuart I Mannering; Michael Elliott; Stuart G Tangye; David C Jackson; Katie L Flanagan; Jamie Rossjohn; Stephanie Gras; Jane Davies; Adrian Miller; Steven Y C Tong; Anthony W Purcell; Katherine Kedzierska
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

7.  SARS-CoV-2-specific CD8+ T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph.

Authors:  Louise C Rowntree; Jan Petersen; Jennifer A Juno; Priyanka Chaurasia; Kathleen Wragg; Marios Koutsakos; Luca Hensen; Adam K Wheatley; Stephen J Kent; Jamie Rossjohn; Katherine Kedzierska; Thi Ho Nguyen
Journal:  Immunol Cell Biol       Date:  2021-06-30       Impact factor: 5.853

8.  Editorial commentary: Host and viral factors in emergent influenza virus infections.

Authors:  David S Hui; Frederick G Hayden
Journal:  Clin Infect Dis       Date:  2014-01-31       Impact factor: 9.079

9.  Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses.

Authors:  Venkata R Duvvuri; Bhargavi Duvvuri; Christilda Alice; Gillian E Wu; Jonathan B Gubbay; Jianhong Wu
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

10.  Broad-Based Influenza-Specific CD8+ T Cell Response without the Typical Immunodominance Hierarchy and Its Potential Implication.

Authors:  Miaojuan Huang; Rong Xu; Cristina Triffon; Nicole Mifsud; Weisan Chen
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.